Skip to main content
    I

    Inhibrx Biosciences, Inc. (INBX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $77.66
    -5.64 (-6.77%)

    Market Cap: $1.23B

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Inhibrx Biosciences, Inc. (INBX) Competitors

    Updated Nov 17, 2026. Similar companies are ranked by business profile, size, sector and industry; metrics come from company filings and market prices.

    The companies most similar to Inhibrx Biosciences are Nurix Therapeutics (NRIX), Innoviva (INVA) and Structure Therapeutics Inc. American Depositary Shares (GPCR). By market cap, Inhibrx Biosciences ranks 9th of the 13 companies on this page; Vir Biotechnology (VIR) is the largest at $1.71B. The median P/E of the 3 companies with a P/E is 6.4x.

    Peer Comparison

    INBX's ROIC of -66.0% is below the peer median of -16.8%, and its revenue growth of -100.0% is below the median of 0.0%. Like the median peer, it pays no dividend.

    CompanyMarket capP/EP/SNet marginROICRev growthDiv yield
    Inhibrx Biosciences (INBX)$1.23BN/A610.4x0.0%-66.0%-100.0%0.00%
    Nurix Therapeutics Inc (NRIX)$1.69B6.4x2.3x42.0%N/A8426.0%0.00%
    Innoviva Inc (INVA)$1.35B5.3x3.0x44.1%10.8%-1.6%0.00%
    Structure Therapeutics Inc. American Depositary Shares (GPCR)$1.43BN/AN/A0.0%N/A0.0%0.00%
    Vir Biotechnology Inc (VIR)$1.71BN/A5.4x-61.0%N/A19582.0%0.00%
    Immix Biopharma Inc (IMMX)$657.09MN/AN/A0.0%-14.9%0.0%0.00%
    Tyra Biosciences Inc (TYRA)$1.38BN/AN/A0.0%N/A0.0%0.00%
    Ultragenyx (RARE)$1.64BN/A2.2x-71.8%N/A8.1%0.00%
    MoonLake Immunotherapeutics (MLTX)$1.06BN/AN/A0.0%-54.6%0.0%0.00%
    Nuvation Bio Inc (NUVB)$1.41BN/A6.7x-67.4%-18.7%242.6%0.00%
    Oric Pharmaceuticals Inc (ORIC)$814.71MN/AN/A0.0%N/A0.0%0.00%
    Forte Biosciences Inc (FBRX)$1.63BN/AN/A0.0%N/A0.0%0.00%
    Theravance Biopharma Inc (TBPH)$884.18M95.1x8.4x51.6%N/A-20.9%0.00%
    Peer median$1.40B6.4x4.2x0.0%-16.8%0.0%0.00%
    Market data as of Nov 17, 2026. Net margin covers the trailing 12 months, Rev growth compares the latest quarter with a year earlier and Div yield is the forward yield. P/E uses earnings per share for the last 12 months as companies report it, often adjusted, so it can show beside a negative net margin, which uses net income. P/E and P/S show N/A when those earnings or sales are negative or missing, or the multiple is above 1,000x.

    Similar Companies

    These are the 12 companies most similar to Inhibrx Biosciences, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.

    CompanyAboutPeers
    Nurix Therapeutics Inc (NRIX)
    Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development...
    NRIX competitors
    Innoviva Inc (INVA)
    Innoviva, Inc. is dedicated to the development and commercialization of pharmaceutical products. The company is headquartered in Burlingame, California.
    INVA competitors
    Structure Therapeutics Inc. American Depositary Shares (GPCR)
    Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic...
    GPCR competitors
    Vir Biotechnology Inc (VIR)
    Vir Biotechnology, Inc., a clinical-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases.
    VIR competitors
    Immix Biopharma Inc (IMMX)
    Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, is dedicated to the development of various tissue-specific therapies in oncology...
    IMMX competitors
    Tyra Biosciences Inc (TYRA)
    Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and improve outcomes...
    TYRA competitors
    Ultragenyx (RARE)
    Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development...
    RARE competitors
    MoonLake Immunotherapeutics (MLTX)
    MoonLake Immunotherapeutics is an innovative biotechnology firm dedicated to advancing therapies for chronic inflammatory diseases through its proprietary drug...
    MLTX competitors
    Nuvation Bio Inc (NUVB)
    Nuvation Bio Inc., a clinical-stage biopharmaceutical company, is focused on developing therapeutic candidates for oncology.
    NUVB competitors
    Oric Pharmaceuticals Inc (ORIC)
    ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of cancers.
    ORIC competitors
    Forte Biosciences Inc (FBRX)
    Forte Biosciences Inc. is a clinical-stage biopharmaceutical company in the United States. The company is headquartered in Torrance, California.
    Theravance Biopharma Inc (TBPH)
    Theravance Biopharma, Inc., a diversified biopharmaceutical company, discovers, develops, and markets organ-selective drugs in the United States, Europe...

    Frequently Asked Questions About INBX

    Who are Inhibrx Biosciences' main competitors?

    The companies most similar to Inhibrx Biosciences include Nurix Therapeutics (NRIX), Innoviva (INVA), Structure Therapeutics Inc. American Depositary Shares (GPCR), Vir Biotechnology (VIR) and Immix Biopharma (IMMX), listed from the closest match.

    Who is Inhibrx Biosciences' biggest competitor?

    Vir Biotechnology (VIR) is the largest of the similar companies at $1.71B; Nurix Therapeutics (NRIX) is the closest match by business profile, size, sector and industry.

    How does INBX stock compare with its competitors?

    INBX's P/S is 610.4x against a peer median of 4.2x; its net margin is 0.0% against a peer median of 0.0%.

    Which of Inhibrx Biosciences' competitors pays a higher dividend?

    Inhibrx Biosciences pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.

    Is Inhibrx Biosciences bigger than its competitors?

    No. Inhibrx Biosciences is 9th by market cap among the 13 companies on this page; the largest is Vir Biotechnology (VIR) at $1.71B.